Perspective Therapeutics announced the Company will present information pertaining to the Company’s sponsored studies of its assets at the Society of Nuclear Medicine & Molecular Imaging, SNMMI, Annual Meeting 2024, which is being held in Toronto, Canada, from June 8-11, 2024. The Company notes that results based on investigator-initiated use of its assets are also being presented. “We are greatly encouraged by the progress of our clinical and preclinical programs,” said Thijs Spoor, CEO of Perspective. “The upcoming presentations at the SNMMI meeting will showcase our activities with VMT-alpha-NET and other promising therapies, underlining our commitment to advancing care for patients battling challenging tumor types.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
- Perspective Therapeutics price target raised to $2.20 from $1.50 at JonesResearch
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
- Perspective Therapeutics reports Q1 EPS (2c), consensus (2c)
- Perspective Therapeutics initiated with an Outperform at RBC Capital